Charting a new course for sustained metabolic health

Redefining Metabolic Health: Sustained, Fat-Selective, Muscle-Preserving Weight Loss

Developing new oral medicines for obesity and associated cardiometabolic diseases

Rivus is a clinical-stage biopharmaceutical company developing new oral investigational medicines for the treatment of obesity and associated cardiometabolic diseases. These oral small molecules are designed for sustained, fat-selective, muscle-preserving weight loss. These medicines leverage validated mechanisms, including mitochondrial uncoupling and GLP-1 agonism to address the limitations of current treatments for these chronic diseases that need new chronic treatment options. 

Rivus’ lead candidate HU6, a best-in-class mitochondrial uncoupler, has been evaluated in three Phase 2 clinical trials, all of which met their primary endpoints. Across these trials, HU6 has demonstrated a favorable efficacy, safety, and tolerability profile in obese patients with MASLD (metabolic dysfunction-associated steatotic liver disease), MASH (metabolic dysfunction-associated steatohepatitis), and HFpEF (heart failure with preserved ejection fraction). These clinical indications are highly prevalent in individuals living with obesity and represent significant unmet needs. In addition, Rivus is developing a pipeline of preclinical therapies, including RV-2895 (differentiated GLP-1) for obesity.